The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | RPM for early CRS detection in patients with multiple myeloma receiving bispecific antibodies
Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, shares insights from a pilot study evaluating remote patient monitoring (RPM) to detect cytokine release syndrome (CRS) earlier in patients with heavily pretreated multiple myeloma receiving bispecific antibodies. Using wearables to track vital signs, the study found that temperature spikes, an early CRS indicator, were detected several hours earlier than with standard clinical care. These findings support the potential for safe outpatient management post-step-up dosing, with future studies aiming to refine this approach. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Since more and more patients with heavily pretreated myeloma receive now bispecific antibodies, they need to go through the step-up dosing phase. And in many countries around the globe, patients are still hospitalized during the step-up dosing. And this can last for 7 to 10 days. And of course, this puts a lot of stress on the healthcare system. So what we did basically is to try to explore to what extent remote patient monitoring could allow us to send patients home after the step-up dosing...
Since more and more patients with heavily pretreated myeloma receive now bispecific antibodies, they need to go through the step-up dosing phase. And in many countries around the globe, patients are still hospitalized during the step-up dosing. And this can last for 7 to 10 days. And of course, this puts a lot of stress on the healthcare system. So what we did basically is to try to explore to what extent remote patient monitoring could allow us to send patients home after the step-up dosing. Because you know with bispecific antibodies targeting BCMA, GPRC5D, 50 to 70 percent of the patients will develop CRS. And although mild or moderate, you want to pick it up early and you don’t want it to be severe. So what we did in 20 patients who received a bispecific antibody in our institute, all patients were hospitalized during the step-up dosing and they underwent routine clinical standard of care. But in parallel and independently, we used remote patient monitoring through wearables where we measured temperature, where we measured the heart rate, respiratory rate and other variables. And our major conclusions from this pilot study was that through this remote patient monitoring or RPM technology, we could pick up CRS significantly earlier than during routine clinical practice. We picked up an increase in temperature on average 4 to 4.5 hours earlier than with the standard routine clinical care. Other parameters like the respiratory rate or heart rate or heart rate variability, they were not predictive for early CRS detection. So this study now will be followed by the next phase where we will send the patients home through the RPM, with the RPM system. And therefore, we believe that also building a flow to make sure that patients who need to come to the hospital can be there rapidly. We believe that it is a safe approach in the near future. Thanks for your attention.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen, BMS, GSJ, Janssen, Sanofi, Pfizer, Roche: Honoraria; Amgen, BMS, GSJ, Janssen, Sanofi, Pfizer, F. Hoffmann-La Roche Ltd: Consultancy; BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Roche: Consultancy, Honoraria; University Hospital Leuven: Consultancy, Honoraria.
